Paper Details

  1. Home
  2. Paper Details

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.

Author: AdvaniRanjana, AlpdoganOnder, BunnVeronica, ChristensenJacob Haaber, Domingo-DomenechEva, FanaleMichelle, FentonKeenan, HorwitzSteven M, IlidgeTim, IyerSwaminathan, MiaoHarry, MorschhauserFranck, O'ConnorOwen A, ProBarbara, PuhlmannMarkus, RossiGiuseppe, SavageKerry J, ShustovAndrei, SuhCheolwon, TobinaiKensei, TrnenyMarek, TrümperLorenz, YuenSam, ZinzaniPier Luigi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This exploratory subgroups analysis evaluated the impact of consolidative stem cell transplant (SCT) on progression-free survival in patients with CD30+ PTCL. The data support the consideration of SCT in patients who achieve complete response following treatment with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone.
Paper Details　
Original Abstract of the Article :
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647727/

データ提供：米国国立医学図書館（NLM）

Stem Cell Transplant: A Potential Treatment for CD30+ PTCL

This study focuses on the potential benefits of stem cell transplant in patients with CD30+ peripheral T-cell lymphoma (PTCL). PTCL is a rare and aggressive type of non-Hodgkin lymphoma that can be difficult to treat. The study found that patients who achieved a complete response to frontline treatment with brentuximab vedotin plus chemotherapy and then underwent a consolidative stem cell transplant had significantly improved progression-free survival. This research is like a beacon of hope in the desert of lymphoma treatment, offering a potential path towards longer-term remission for patients with CD30+ PTCL.

Stem Cell Transplant: A New Avenue for PTCL Treatment

This study suggests that stem cell transplant may be a valuable option for patients with CD30+ PTCL who achieve a complete response to frontline therapy. This is like discovering a hidden oasis in the desert of lymphoma treatment, offering a potential path towards a longer-term remission for patients with this challenging disease.

Navigating Lymphoma Treatment: Seeking Long-Term Remission

This research highlights the importance of considering all available treatment options for PTCL, including stem cell transplant. It's like a map guiding us through the desert of lymphoma treatment, helping us find the most effective path towards long-term remission and improved quality of life for patients.

Dr.Camel's Conclusion

This study provides promising evidence for the use of stem cell transplant in patients with CD30+ PTCL, offering a glimmer of hope in the desert of lymphoma treatment. It's a reminder that even in the most challenging cases, there are often new avenues to explore, and new oases to discover, in our pursuit of better treatment outcomes.

Date :
  1. Date Completed 2022-10-07
  2. Date Revised 2022-11-16
Further Info :

Pubmed ID

35470385

DOI: Digital Object Identifier

PMC9647727

Related Literature

Article Analysis
・Effects of brentuximab vedotin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.